Evidence map›Paper›PMID 41659404›Full record

ArticlebioRxiv : the preprint server for biology2026

Global mRNA 3'UTR lengthening in small-cell neuroendocrine carcinoma.

Yi Zhang, Xiaofan Zhao, Huan Wang, Ya-Mei Hu, Xiao-Xin Sun, Faming Zhao, Shunyu Du, Roselyn S Dai, Nicole K Andeen, Rosalie C Sears and 7 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Yi ZhangDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0001-5680-4647
Xiaofan ZhaoDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
Huan WangDepartment of Cardiothoracic Surgery, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, Zhejiang, China.
Ya-Mei HuDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
Xiao-Xin SunKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Faming ZhaoDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0002-8238-3863
Shunyu DuDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.
Roselyn S DaiDepartment of Molecular and Medical Genetics, Oregon Health & Science University, Portland, OR, USA.
Nicole K AndeenDepartment of Pathology, Oregon Health & Science University, Portland, OR, USA.
Rosalie C SearsKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0003-1558-2413
Eva CoreyDepartment of Urology, University of Washington, Seattle, Washington, USA.
Jonathan R BrodyKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Joshi J AlumkalDepartment of Internal Medicine, Rogel Cancer Center, University of Michigan, Ann Arbor, MI, USA.
Gordon B MillsDivision of Oncological Sciences, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA, USA.
Mu-Shui DaiKnight Cancer Institute, Oregon Health & Science University, Portland, OR, USA.
Zheng XiaDepartment of Biomedical Engineering, Oregon Health & Science University, Portland, OR, USA.ORCID 0000-0003-3364-8324

Funding

TRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI PETER S NELSON · 2002 to 2026
$58.1M
Steroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI PETER S NELSON · 2013 to 2026
$25.0M
The Molecular Drivers and Therapeutic Susceptibilities in Lineage State Transitions of Metastatic Prostate CancerP01CA298991 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI Joshua Lang · 2025 to 2026
$7.6M
Evaluating prostate cancer phenotype and genotype classification from circulating tumor DNA as biomarkers for predicting treatment outcomesR01CA280056 · NCI · FRED HUTCHINSON CANCER CENTER · PI Gavin Ha, PETER S NELSON · 2023 to 2026
$2.4M
Regulation of the nucleolar RNA exosome in cancerR01CA262104 · NCI · OREGON HEALTH & SCIENCE UNIVERSITY · PI Mu-Shui Dai · 2022 to 2026
$2.3M
Targeting Vulnerabilities Exposed by Cancer Treatment-Induced Lineage PlasticityR01CA266452 · NCI · FRED HUTCHINSON CANCER CENTER · PI PETER S NELSON · 2022 to 2026
$2.0M
High Performance Computing and Machine Learning Infrastructure for Oregon Life SciencesS10OD034224 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI ELLROTT, KYLE · 2023 to 2023
$2.0M
Targeting Prostate Cancer Lineage Plasticity with BET Bromodomain InhibitionR01CA251245 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ALUMKAL, JOSHI JAMES · 2020 to 2024
$1.9M
Developing New Treatment Strategies for Neuroendocrine Prostate CancerR01CA282005 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Joshi James Alumkal · 2024 to 2026
$1.6M
Characterizing phenotype-associated subpopulations from single-cell sequencing dataR01GM147365 · NIGMS · OREGON HEALTH & SCIENCE UNIVERSITY · PI Zheng Xia · 2023 to 2026
$1.2M
NCI NIH HHS P01 CA163227NCI NIH HHS P01 CA298991NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA251245NCI NIH HHS R01 CA262104NCI NIH HHS R01 CA266452NCI NIH HHS R01 CA280056NCI NIH HHS R01 CA282005NIGMS NIH HHS R01 GM147365NIH HHS S10 OD034224
6 · The paper itself

Abstract

Small-cell neuroendocrine carcinoma (SCNC) is a rare but highly malignant tumor subtype that primarily arises in the lung, also rarely in other organs, and as a consequence of treatment induced lineage transdifferentiation of prostate adenocarcinomas. The molecular convergence of SCNC across diverse tissues enables its identification through conserved SCNC-specific molecular markers, facilitating tumor subtype classification. As a critical post-transcriptional regulatory mechanism, alternative polyadenylation (APA) modulates 3'UTR length and significantly impacts tumor progression. However, its role in SCNC remains largely unclear. Here, we report a global 3'UTR lengthening pattern driven by APA in SCNC. We identified a set of conserved 3'UTR lengthening events across SCNCs of different tissue origins, which are strongly associated with neural development and related signaling pathways. Furthermore, we developed a neural network-based prediction model to classify SCNC by leveraging these specific APA signatures. Our study provides new insights into the post-transcriptional landscape of SCNCs and highlights APA signatures as promising biomarkers for SCNC identification.

Indexed as

3’UTRalternative polyadenylationneuroendocrine prostate cancersmall-cell lung cancersmall-cell neuroendocrine carcinoma

Identifiers

PMID41659404
PMCPMC12873799

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.